Posted in Job News, News
Naynesh Mistry is recruiting for a Technical Lead (Nutrition) to join a leading biopharmaceutical company in Yorkshire on a permanent basis.
In this position you will be required to Monitor/evaluate the scientific and quality performance of routine assays through control charts and be responsible for completing Out of Specification (OOS) reports, Corrective Action/Preventative Action (CAPA) reports.
Posted in News
Naynesh Mistry is recruiting for Research Scientists (Nutrition) to join a leading Biopharmaceutical company based in Yorkshire on a permanent basis.
Responsibilities in this role include organising, conducting and evaluating analytical results, and testing independently in compliance with applicable methods, protocols, SOPs and regulatory agency guidelines. You will also be required to maintain, operate and perform routine and non-routine maintenance on laboratory equipment and software.
To apply for this position you should have demonstrable experience in laboratories and be proficient using, and trouble shooting analytical equipment.
Posted in Jobs, News
As reported by The Wall Street Journal, the generic drug company, Dr Reddy’s Laboratories is to team up with Merck Serono’s biopharmaceutical division to develop biosimilars to be sold in the U.S, Europe and Japan.
The partnership will see the two companies co-develop a portfolio of biosimilars and will focus mainly on monoclonal antibodies. Dr Reddys and Merck Serono will work together to co-develop, manufacture and commercialise the compounds around the world.
Dr Reddy’s are a leader in the development of biosimilars and their partnership with Merck Serono will further strengthen their presence in the biosimilar space in emerging markets.
The deal will seek to benefit from a new market due to patents on biotech drugs expiring. Historically, these medicines have been safe from generic competition, however, the development of biosimilar versions of these drugs could mean that high quality, low cost versions of the biotechnology drugs will soon become widely available.
Merck is hoping to protect itself from this risk by collaborating with Dr Reddy’s to develop co-molecules. Under the
agreement, Dr Reddy’s will lead the early product development and complete Phase 1 development, before handing it over to Merck for manufacturing and late-stage Phase III trials.
Posted in Jobs, News
As reported by The Pharma Times, the leading Biotechnology company, Amgen is acquiring KAI Pharmaceuticals, a biopharmaceutical company who has developed a novel drug for chronic kidney disease.
Amgen have acquired KAI Pharmaceuticals for $315 million in cash which has given them rights to the experimental treatment for chronic kidney disease.
The kidney drug, called KAI-4169 is in Phase II and is being researched for the treatment of secondary hyperparathyroidism (SHPT) in those patients who are suffering with chronic kidney disease and are on dialysis. It is a drug that is administered intravenously.
The world’s largest biotech company, Amgen has given a loan to KAI to enable the Phase III trials to take place. The acquisition of KAI Pharmaceuticals will add to their already established dialysis drug portfolio (if it is approved). Amgen already have a drug used for the treatment of SHPT called Sensipar which is an oral drug.
Are you looking for a job in the Biotechnology Industry? Click here to search our current Biotech jobs online now.
Posted in Industry News, Mobile News, News
Biopharmaceutical company Quintiles is looking to establish more UK sites, creating pharmaceutical and clinical jobs, reports pharmatimes.com.
The US company sees the UK as a good place for clinical trials and is hoping to open at least two more Prime Sites to go alongside the one at Queen Mary, University of London. Including two other current sites, Quintiles employs 2,000 people in the UK, a figure set to rise with the planned opening of the new Prime Sites.
Lindy Jones, Quintiles head of global integrated site services, says the UK is of “significant interested to us,” with fifty trials currently being run at the Queen Mary site. Jones believe that the UK “has opened up far more to clinical research” in the past eighteen months, meaning that Quintiles is considering opening “an additional two, maybe three Prime Sites in the UK.”
Looking for a job in the science industry? Start by clicking here, now